Trials / Completed
CompletedNCT02634437
Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects
A Single-Dose, Open-Label, Pharmacokinetic Study Of Ulipristal Acetate In Healthy Subjects With Normal Renal Function And Patients With Moderately Or Severly Impaired Renal Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Allergan · Industry
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to observe the effect of renal function on the pharmacokinetic, safety, and tolerability profiles of Ulipristal acetate following administration of a single oral dose of a 10 mg Ulipristal acetate tablet.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ulipristal acetate |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2016-12-09
- Completion
- 2016-12-09
- First posted
- 2015-12-18
- Last updated
- 2018-02-08
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02634437. Inclusion in this directory is not an endorsement.